BB Biotech Reports Q3 2026 Net Profit CHF 175 Mln

By Reuters News

- BB BIOTECH AG BION.S:

  • Q3 2026 NAV RETURNED 5.6% IN CHF; SHARE PRICE RETURNED 6.5% IN CHF

  • Q3 2026 NET PROFIT AMOUNTED TO CHF 175 MILLION

  • SEES SELECTIVE OPPORTUNITIES IN COMPANIES WHOSE SHARE PRICES HAVE FALLEN WITHOUT A CORRESPONDING CHANGE IN THEIR CLINICAL PROSPECTS

Further company coverage: BION.S

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk